Format
Sort by
Items per page

Send to

Choose Destination

Best matches for de Thé H[au]:

Obituary for guy de thé. de Thé H et al. Retrovirology. (2015)

Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. de Thé H et al. Cancer Cell. (2017)

Differentiation therapy revisited. de Thé H et al. Nat Rev Cancer. (2018)

Search results

Items: 1 to 50 of 252

1.

A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.

Auvin S, Öztürk H, Abaci YT, Mautino G, Meyer-Losic F, Jollivet F, Bashir T, de Thé H, Sahin U.

Life Sci Alliance. 2019 Aug 20;2(4). pii: e201800213. doi: 10.26508/lsa.201800213. Print 2019 Aug.

2.

Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia.

McKenzie MD, Ghisi M, Oxley EP, Ngo S, Cimmino L, Esnault C, Liu R, Salmon JM, Bell CC, Ahmed N, Erlichster M, Witkowski MT, Liu GJ, Chopin M, Dakic A, Simankowicz E, Pomilio G, Vu T, Krsmanovic P, Su S, Tian L, Baldwin TM, Zalcenstein DA, DiRago L, Wang S, Metcalf D, Johnstone RW, Croker BA, Lancaster GI, Murphy AJ, Naik SH, Nutt SL, Pospisil V, Schroeder T, Wall M, Dawson MA, Wei AH, de Thé H, Ritchie ME, Zuber J, Dickins RA.

Cell Stem Cell. 2019 Aug 1;25(2):258-272.e9. doi: 10.1016/j.stem.2019.07.001.

PMID:
31374198
3.

Primitive macrophages are dispensable for HSPC mobilization and definitive hematopoiesis.

Yuan H, Gao S, Chen H, Liu X, Zhou J, de The H, Zhu J.

Blood. 2019 Aug 29;134(9):782-784. doi: 10.1182/blood.2018893974. Epub 2019 Jul 16. No abstract available.

PMID:
31311814
4.

Interferon regulatory factor 2 binding protein 2b regulates neutrophil versus macrophage fate during zebrafish definitive myelopoiesis.

Wang L, Gao S, Wang H, Xue C, Liu X, Yuan H, Wang Z, Chen S, Chen Z, de Thé H, Zhang Y, Zhang W, Zhu J, Zhou J.

Haematologica. 2019 May 23. pii: haematol.2019.217596. doi: 10.3324/haematol.2019.217596. [Epub ahead of print]

5.

TAMM41 is required for heart valve differentiation via regulation of PINK-PARK2 dependent mitophagy.

Yang RM, Tao J, Zhan M, Yuan H, Wang HH, Chen SJ, Chen Z, de Thé H, Zhou J, Guo Y, Zhu J.

Cell Death Differ. 2019 Nov;26(11):2430-2446. doi: 10.1038/s41418-019-0311-z. Epub 2019 Mar 1.

PMID:
30824836
6.

FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Esnault C, Rahmé R, Rice KL, Berthier C, Gaillard C, Quentin S, Maubert AL, Kogan S, de Thé H.

Blood. 2019 Mar 28;133(13):1495-1506. doi: 10.1182/blood-2018-07-866095. Epub 2019 Jan 23.

7.

Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia.

Gaillard C, Surianarayanan S, Bentley T, Warr MR, Fitch B, Geng H, Passegué E, de Thé H, Kogan SC.

Blood Adv. 2018 Oct 9;2(19):2462-2466. doi: 10.1182/bloodadvances.2018018929.

8.

Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation.

Gachet S, El-Chaar T, Avran D, Genesca E, Catez F, Quentin S, Delord M, Thérizols G, Briot D, Meunier G, Hernandez L, Pla M, Smits WK, Buijs-Gladdines JG, Van Loocke W, Menschaert G, André-Schmutz I, Taghon T, Van Vlierberghe P, Meijerink JP, Baruchel A, Dombret H, Clappier E, Diaz JJ, Gazin C, de Thé H, Sigaux F, Soulier J.

Cancer Discov. 2018 Dec;8(12):1614-1631. doi: 10.1158/2159-8290.CD-17-0831. Epub 2018 Sep 28.

PMID:
30266814
9.

PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers.

Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemati F, Hurbain I, Raposo G, Popova T, Stern MH, Lallemand-Breitenbach V, Müller S, Cañeque T, Rodriguez R, Vincent-Salomon A, de Thé H, Rossignol R, Mechta-Grigoriou F.

Cell Metab. 2019 Jan 8;29(1):156-173.e10. doi: 10.1016/j.cmet.2018.09.002. Epub 2018 Sep 20.

10.

Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.

Lehmann-Che J, Bally C, Letouzé E, Berthier C, Yuan H, Jollivet F, Ades L, Cassinat B, Hirsch P, Pigneux A, Mozziconacci MJ, Kogan S, Fenaux P, de Thé H.

Nat Commun. 2018 May 24;9(1):2047. doi: 10.1038/s41467-018-04384-5.

11.

Publisher Correction: RING tetramerization is required for nuclear body biogenesis and PML sumoylation.

Wang P, Benhenda S, Wu H, Lallemand-Breitenbach V, Zhen T, Jollivet F, Peres L, Li Y, Chen SJ, Chen Z, de Thé H, Meng G.

Nat Commun. 2018 May 4;9(1):1841. doi: 10.1038/s41467-018-04347-w.

12.

PML nuclear bodies: from architecture to function.

Lallemand-Breitenbach V, de Thé H.

Curr Opin Cell Biol. 2018 Jun;52:154-161. doi: 10.1016/j.ceb.2018.03.011. Epub 2018 Apr 30. Review.

PMID:
29723661
13.

RNF4 regulates zebrafish granulopoiesis through the DNMT1-C/EBPα axis.

Wang L, Liu X, Wang H, Yuan H, Chen S, Chen Z, de The H, Zhou J, Zhu J.

FASEB J. 2018 Sep;32(9):4930-4940. doi: 10.1096/fj.201701450RR. Epub 2018 Apr 10.

PMID:
29634367
14.

RING tetramerization is required for nuclear body biogenesis and PML sumoylation.

Wang P, Benhenda S, Wu H, Lallemand-Breitenbach V, Zhen T, Jollivet F, Peres L, Li Y, Chen SJ, Chen Z, de Thé H, Meng G.

Nat Commun. 2018 Mar 29;9(1):1277. doi: 10.1038/s41467-018-03498-0. Erratum in: Nat Commun. 2018 May 4;9(1):1841.

15.

Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner.

Dubuisson L, Lormières F, Fochi S, Turpin J, Pasquier A, Douceron E, Oliva A, Bazarbachi A, Lallemand-Breitenbach V, De Thé H, Journo C, Mahieux R.

Oncogene. 2018 May;37(21):2806-2816. doi: 10.1038/s41388-018-0163-x. Epub 2018 Mar 6.

PMID:
29507418
16.

The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia.

Di Costanzo A, Del Gaudio N, Conte L, Dell'Aversana C, Vermeulen M, de Thé H, Migliaccio A, Nebbioso A, Altucci L.

Oncogene. 2018 May;37(19):2559-2572. doi: 10.1038/s41388-018-0143-1. Epub 2018 Feb 22.

17.

Differentiation therapy revisited.

de Thé H.

Nat Rev Cancer. 2018 Feb;18(2):117-127. doi: 10.1038/nrc.2017.103. Epub 2017 Dec 1. Review.

PMID:
29192213
18.

Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure.

de Thé H, Pandolfi PP, Chen Z.

Cancer Cell. 2017 Nov 13;32(5):552-560. doi: 10.1016/j.ccell.2017.10.002. Review.

19.

PML is a ROS sensor activating p53 upon oxidative stress.

Niwa-Kawakita M, Ferhi O, Soilihi H, Le Bras M, Lallemand-Breitenbach V, de Thé H.

J Exp Med. 2017 Nov 6;214(11):3197-3206. doi: 10.1084/jem.20160301. Epub 2017 Sep 20.

20.

GATA5 SUMOylation is indispensable for zebrafish cardiac development.

Wen B, Yuan H, Liu X, Wang H, Chen S, Chen Z, de The H, Zhou J, Zhu J.

Biochim Biophys Acta Gen Subj. 2017 Jul;1861(7):1691-1701. doi: 10.1016/j.bbagen.2017.03.005. Epub 2017 Mar 8.

PMID:
28285006
21.

Promyelocytic Leukemia Protein (PML) Controls Listeria monocytogenes Infection.

Ribet D, Lallemand-Breitenbach V, Ferhi O, Nahori MA, Varet H, de Thé H, Cossart P.

MBio. 2017 Jan 10;8(1). pii: e02179-16. doi: 10.1128/mBio.02179-16.

22.

Promyelocytic Leukemia Protein, a Protein at the Crossroad of Oxidative Stress and Metabolism.

Tessier S, Martin-Martin N, de Thé H, Carracedo A, Lallemand-Breitenbach V.

Antioxid Redox Signal. 2017 Mar 20;26(9):432-444. doi: 10.1089/ars.2016.6898. Epub 2016 Dec 12. Review.

PMID:
27758112
23.

Detection of Protein SUMOylation In Situ by Proximity Ligation Assays.

Sahin U, Jollivet F, Berthier C, de Thé H, Lallemand-Breitenbach V.

Methods Mol Biol. 2016;1475:139-50. doi: 10.1007/978-1-4939-6358-4_10.

PMID:
27631803
24.

Comment on "SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML".

Ferhi O, Pérès L, Tessier S, de Thé H, Lallemand-Breitenbach V.

Sci Signal. 2016 Aug 9;9(440):tc1. doi: 10.1126/stke.9.440.tc1.

PMID:
27507651
25.

A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma.

Dvorkina M, Nieddu V, Chakelam S, Pezzolo A, Cantilena S, Leite AP, Chayka O, Regad T, Pistorio A, Sementa AR, Virasami A, Barton J, Montano X, Lechertier T, Brindle N, Morgenstern D, Lebras M, Burns AJ, Saunders NJ, Hodivala-Dilke K, Bagella L, De The H, Anderson J, Sebire N, Pistoia V, Sala A, Salomoni P.

Clin Cancer Res. 2016 Jul 1;22(13):3398-409. doi: 10.1158/1078-0432.CCR-15-2081. Epub 2016 Apr 13. Erratum in: Clin Cancer Res. 2017 Feb 1;23 (3):870.

26.

p53 as an Effector or Inhibitor of Therapy Response.

Ablain J, Poirot B, Esnault C, Lehmann-Che J, de Thé H.

Cold Spring Harb Perspect Med. 2015 Dec 4;6(1):a026260. doi: 10.1101/cshperspect.a026260. Review.

27.

PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.

Ivanschitz L, Takahashi Y, Jollivet F, Ayrault O, Le Bras M, de Thé H.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14278-83. doi: 10.1073/pnas.1507540112. Epub 2015 Nov 2.

28.

CCAAT/enhancer-binding protein α is required for hepatic outgrowth via the p53 pathway in zebrafish.

Yuan H, Wen B, Liu X, Gao C, Yang R, Wang L, Chen S, Chen Z, de The H, Zhou J, Zhu J.

Sci Rep. 2015 Oct 29;5:15838. doi: 10.1038/srep15838.

29.

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes.

Bally C, Renneville A, Preudhomme C, Legrand M, Adès L, de Thé H, Fenaux P, Lehmann-Che J.

Leuk Res. 2015 Jul 4. pii: S0145-2126(15)30344-1. doi: 10.1016/j.leukres.2015.07.001. [Epub ahead of print]

PMID:
26271412
30.

Lessons taught by acute promyelocytic leukemia cure.

de Thé H.

Lancet. 2015 Jul 18;386(9990):247-8. doi: 10.1016/S0140-6736(15)61278-8. No abstract available.

PMID:
26194524
31.

Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.

Gaillard C, Tokuyasu TA, Rosen G, Sotzen J, Vitaliano-Prunier A, Roy R, Passegué E, de Thé H, Figueroa ME, Kogan SC.

Haematologica. 2015 Aug;100(8):1064-75. doi: 10.3324/haematol.2014.123018. Epub 2015 Jun 18.

32.

DNA methyltransferase 1 functions through C/ebpa to maintain hematopoietic stem and progenitor cells in zebrafish.

Liu X, Jia X, Yuan H, Ma K, Chen Y, Jin Y, Deng M, Pan W, Chen S, Chen Z, de The H, Zon LI, Zhou Y, Zhou J, Zhu J.

J Hematol Oncol. 2015 Feb 22;8:15. doi: 10.1186/s13045-015-0115-7.

33.

Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells.

El Hajj H, Dassouki Z, Berthier C, Raffoux E, Ades L, Legrand O, Hleihel R, Sahin U, Tawil N, Salameh A, Zibara K, Darwiche N, Mohty M, Dombret H, Fenaux P, de Thé H, Bazarbachi A.

Blood. 2015 May 28;125(22):3447-54. doi: 10.1182/blood-2014-11-612416. Epub 2015 Mar 23.

PMID:
25800051
34.

Sumoylation of CCAAT/enhancer-binding protein α is implicated in hematopoietic stem/progenitor cell development through regulating runx1 in zebrafish.

Yuan H, Zhang T, Liu X, Deng M, Zhang W, Wen Z, Chen S, Chen Z, de The H, Zhou J, Zhu J.

Sci Rep. 2015 Mar 11;5:9011. doi: 10.1038/srep09011.

35.

Obituary for guy de thé.

de Thé H, Gessain A.

Retrovirology. 2015 Jan 31;12:7. doi: 10.1186/s12977-014-0128-2. No abstract available.

36.

Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.

Netter J, Lehmann-Che J, Lambert J, Tallet A, Lourenco N, Soliman H, Bertheau P, Pariente B, Chirica M, Pocard M, Allez M, De The H, Gornet JM.

Bull Cancer. 2015 Feb;102(2):117-25. doi: 10.1016/j.bulcan.2014.12.010. Epub 2015 Jan 20.

37.

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.

de Cremoux P, Dalvai M, N'Doye O, Moutahir F, Rolland G, Chouchane-Mlik O, Assayag F, Lehmann-Che J, Kraus-Berthie L, Nicolas A, Lockhart BP, Marangoni E, de Thé H, Depil S, Bystricky K, Decaudin D.

Breast Cancer Res Treat. 2015 Jan;149(1):81-9. doi: 10.1007/s10549-014-3233-y. Epub 2014 Dec 12.

PMID:
25503779
38.

PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.

Sahin U, de Thé H, Lallemand-Breitenbach V.

Nucleus. 2014;5(6):499-507. doi: 10.4161/19491034.2014.970104. Review.

39.

ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation.

Dassouki Z, Sahin U, El Hajj H, Jollivet F, Kfoury Y, Lallemand-Breitenbach V, Hermine O, de Thé H, Bazarbachi A.

Blood. 2015 Jan 15;125(3):474-82. doi: 10.1182/blood-2014-04-572750. Epub 2014 Nov 13.

PMID:
25395419
40.

Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.

Vitaliano-Prunier A, Halftermeyer J, Ablain J, de Reynies A, Peres L, Le Bras M, Metzger D, de Thé H.

Blood. 2014 Dec 11;124(25):3772-80. doi: 10.1182/blood-2014-03-561852. Epub 2014 Sep 25.

PMID:
25258343
41.

Resistance to therapy in acute promyelocytic leukemia.

Lehmann-Che J, Bally C, de Thé H.

N Engl J Med. 2014 Sep 18;371(12):1170-2. doi: 10.1056/NEJMc1409040. No abstract available.

PMID:
25229938
42.

PML nuclear bodies: regulation, function and therapeutic perspectives.

Sahin U, Lallemand-Breitenbach V, de Thé H.

J Pathol. 2014 Nov;234(3):289-91. doi: 10.1002/path.4426. Review.

PMID:
25138686
43.

Retinoic acid signaling in cancer: The parable of acute promyelocytic leukemia.

Ablain J, de Thé H.

Int J Cancer. 2014 Nov 15;135(10):2262-72. doi: 10.1002/ijc.29081. Epub 2014 Aug 14. Review.

44.

The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.

Liu X, Yuan H, Peres L, Chen S, Chen Z, de The H, Zhou J, Zhu J.

PLoS One. 2014 Aug 13;9(8):e104906. doi: 10.1371/journal.pone.0104906. eCollection 2014.

45.

Interferon controls SUMO availability via the Lin28 and let-7 axis to impede virus replication.

Sahin U, Ferhi O, Carnec X, Zamborlini A, Peres L, Jollivet F, Vitaliano-Prunier A, de Thé H, Lallemand-Breitenbach V.

Nat Commun. 2014 Jun 19;5:4187. doi: 10.1038/ncomms5187.

PMID:
24942926
46.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P.

Leuk Res. 2014 Jul;38(7):751-5. doi: 10.1016/j.leukres.2014.03.012. Epub 2014 Mar 23.

PMID:
24836762
47.

Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins.

Sahin U, Ferhi O, Jeanne M, Benhenda S, Berthier C, Jollivet F, Niwa-Kawakita M, Faklaris O, Setterblad N, de Thé H, Lallemand-Breitenbach V.

J Cell Biol. 2014 Mar 17;204(6):931-45. doi: 10.1083/jcb.201305148.

48.

The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies.

Rice KL, de Thé H.

J Intern Med. 2014 Jul;276(1):61-70. doi: 10.1111/joim.12208.

49.

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.

Giacchetti S, Porcher R, Lehmann-Che J, Hamy AS, de Roquancourt A, Cuvier C, Cottu PH, Bertheau P, Albiter M, Bouhidel F, Coussy F, Extra JM, Marty M, de Thé H, Espié M.

Br J Cancer. 2014 Mar 18;110(6):1413-9. doi: 10.1038/bjc.2014.81. Epub 2014 Feb 25.

50.

Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392.

De Bellis F, Carafa V, Conte M, Rotili D, Petraglia F, Matarese F, Françoijs KJ, Ablain J, Valente S, Castellano R, Goubard A, Collette Y, Mandoli A, Martens JH, de Thé H, Nebbioso A, Mai A, Stunnenberg HG, Altucci L.

Cancer Res. 2014 Apr 15;74(8):2328-39. doi: 10.1158/0008-5472.CAN-13-2568. Epub 2014 Feb 24.

Supplemental Content

Loading ...
Support Center